Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $88.43 Average PT from Analysts

Structure Therapeutics Inc. (NASDAQ:GPCR) has received a consensus rating of “Buy” from the seven analysts that are covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $87.83.

A number of research analysts have recently weighed in on the stock. JMP Securities dropped their price objective on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research note on Friday, August 9th. Morgan Stanley began coverage on Structure Therapeutics in a research note on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a research report on Monday, September 23rd.

Structure Therapeutics Trading Up 1.7 %

Shares of GPCR stock opened at $42.99 on Tuesday. The stock has a 50 day simple moving average of $38.73 and a 200-day simple moving average of $40.09. The company has a market cap of $2.00 billion, a price-to-earnings ratio of -55.83 and a beta of -3.53. Structure Therapeutics has a 12-month low of $26.61 and a 12-month high of $75.02.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. On average, equities analysts forecast that Structure Therapeutics will post -0.86 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC increased its holdings in Structure Therapeutics by 4.5% in the second quarter. Squarepoint Ops LLC now owns 14,449 shares of the company’s stock valued at $567,000 after buying an additional 617 shares during the last quarter. Sandia Investment Management LP acquired a new position in shares of Structure Therapeutics in the 2nd quarter worth approximately $39,000. Brandywine Managers LLC increased its holdings in shares of Structure Therapeutics by 9.2% in the 4th quarter. Brandywine Managers LLC now owns 12,007 shares of the company’s stock valued at $489,000 after acquiring an additional 1,007 shares during the last quarter. Quarry LP acquired a new stake in shares of Structure Therapeutics during the 2nd quarter valued at approximately $79,000. Finally, Teachers Retirement System of The State of Kentucky lifted its stake in Structure Therapeutics by 17.8% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 13,733 shares of the company’s stock worth $589,000 after purchasing an additional 2,077 shares during the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.